Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Gastrointestinal disorders – page 84

  • 1 123 clinical trials
  • 490 recruiting
  • 469 conditions
  • 28 countries

Conditions in this area

469 conditions with trials, the busiest first

Colitis ulcerative120Colorectal cancer metastatic105Crohn's disease94Colorectal cancer89Pancreatic carcinoma57Gastric cancer55Oesophageal adenocarcinoma48Systemic scleroderma39Pancreatic carcinoma metastatic35Adenocarcinoma pancreas34Rectal cancer33Oesophageal carcinoma32Sjogren's syndrome29Adenocarcinoma gastric28Ovarian cancer27Non-small cell lung cancer26Breast cancer25Colon cancer25Gastrooesophageal cancer25Cystic fibrosis24Hepatocellular carcinoma18Fallopian tube cancer17Endometrial cancer16Gastroenteropancreatic neuroendocrine tumour disease16+445

Clinical trials in Gastrointestinal disorders

1 123 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 123 clinical trials

Squamous cell carcinoma of head and neck+7

Not recruiting

Study on the Safety and Effects of Durvalumab and Tremelimumab with Radiotherapy for Patients with Metastatic Squamous Cell Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Institut Gustave Roussy

Paraganglion neoplasm+3

Not recruiting

Study on the Safety of Lutetium (177Lu) Oxodotreotide, L-Lysine Hydrochloride, and L-Arginine Hydrochloride in Adolescents with Neuroendocrine Tumors and PPGLs

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:L-Arginine Hydrochloride
  • Sponsor:Advanced Accelerator Applications

Gastric cancer

Not recruiting

Study on Ramucirumab and Paclitaxel for Older Patients with Advanced Stomach Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Paclitaxel
  • Sponsor:Fondation Franc.Cancerologie Digestive

Colorectal cancer metastatic+4

Not recruiting

Study on the Safety and Effects of ICT01, Aldesleukin, and Pembrolizumab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Aldesleukin
  • Sponsor:Imcheck Therapeutics

Gastroenteropancreatic neuroendocrine tumour disease

Not recruiting

Study of Lutetium (177Lu) Edotreotide compared to standard treatment in patients with aggressive Grade 2 and Grade 3 gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:ITM Solucin GmbH

Gastrointestinal carcinoma

Not recruiting

Study on the Effects of Methylprednisolone and Sodium Chloride in Patients Undergoing Surgery for Digestive Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Centre Hospitalier Universitaire De Dijon

Oesophageal disorder+1

Not recruiting

Study on Botulinum Toxin Type A Injection for Patients with Inability to Belch Due to Retrograde Cricopharyngeus Dysfunction

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Sodium Chloride
  • Sponsor:Algemeen Ziekenhuis Delta

Anal cancer+5

Not recruiting

Study of TG4001 and Avelumab for Patients with Advanced HPV-16 Positive Cancers

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Transgene

Colon cancer+5

Not recruiting

Study on Selpercatinib for Adults with Advanced or Metastatic Solid Tumors with RET Activation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Selpercatinib
  • Sponsor:Eli Lilly & Co.

Adenoid cystic carcinoma of salivary gland

Not recruiting

Study on the Safety and Effectiveness of Lutetium (177Lu) Vipivotide Tetraxetan for Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Lutetium (177Lu) Vipivotide Tetraxetan
  • Sponsor:Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie-Panstwowy Instytut Badawczy

Gastrooesophageal cancer

Not recruiting

Study on Regorafenib and Nivolumab for Patients with Advanced Gastro-Oesophageal Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Institut fuer Klinische Krebsforschung IKF GmbH

Morning sickness

Not recruiting

Study on Doxylamine and Pyridoxine for Pregnant Women with Nausea and Vomiting

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Doxylamine Hydrogen Succinate
  • Sponsor:Itf Research Pharma S.L.

Substances studied in this area

The therapies tested most often in Gastrointestinal disorders trials.

Fluorouracil205 clinical trialsOxaliplatin195 clinical trialsCapecitabine108 clinical trialsFolinic Acid83 clinical trialsBevacizumab72 clinical trialsCalcium Folinate67 clinical trialsPembrolizumab57 clinical trialsIrinotecan Hydrochloride Trihydrate52 clinical trialsNivolumab48 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.